Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance

Author(s): Manu Asthana, Sushil Kumar Sahu, Amit Kumar, Suchitra Mohanty, Sudipta Chakrabarti, Piyanki Das, Nabanita Roy Chattopadhya, Koustav Chatterjee, Shivaram Prasad Singh, Shanmugam Rajasubramaniam, Tathagata Choudhuri*

Journal Name: Current Drug Metabolism

Volume 19 , Issue 3 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Interleukin-28B (IL28B) locus on a human chromosomal region mapped to 19q13 execute immune defense against viruses. During Hepatitis C Virus (HCV) infection the IL28B has a promising role in deciding the consequence of infection for spontaneous clearance of viruses or causing chronic liver infection. Treatment of chronic hepatitis C includes use of direct acting antivirals, Pegylated-Interferon (PEG-IFN) and Ribavirin (RBV) therapy. Also, interferon free regimens are suggested to be useful in resistant patients. Numerous reports including Genome-Wide Association Studies (GWAS), comprehensive meta-analysis and independent case-control studies in different population have revealed the association between certain Il-28B polymorphisms and response to the PEGIFN- RBV therapy in patients infected with HCV.

Method: We searched all peer-reviewed relevant and recent literature manually for the present review.

Conclusion: The GWAS studies have revealed an important role of IL28B in HCV infection, which was supported by many independent studies and meta-analysis by different groups in different ethnicities. IL28B genotyping may be use as predictors of response for IFN-based therapy and personalized treatment of hepatitis C patient.

Keywords: HCV, sustained virological response, IL28B, pegylated-interferon, ribavirin therapy, GWAS.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 08 May, 2018
Page: [215 - 223]
Pages: 9
DOI: 10.2174/1389200219666180129115359
Price: $65

Article Metrics

PDF: 24
PRC: 1